| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
|
Tolaney, Sara M
|
|
|
21 |
6 |
p. 763-775
|
artikel
|
| 2 |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee, Michael S
|
|
|
21 |
6 |
p. 808-820
|
artikel
|
| 3 |
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
|
Huang, Jing
|
|
|
21 |
6 |
p. 832-842
|
artikel
|
| 4 |
Cancer detection: the quest for a single liquid biopsy for all
|
The Lancet Oncology,
|
|
|
21 |
6 |
p. 733
|
artikel
|
| 5 |
CDK4/6 inhibition in HER2-positive breast cancer
|
Battisti, Nicolò Matteo Luca
|
|
|
21 |
6 |
p. 734-735
|
artikel
|
| 6 |
Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward
|
Bhoori, Sherrie
|
|
|
21 |
6 |
p. 740-741
|
artikel
|
| 7 |
Correction to Lancet Oncol 2020; 21:750–51
|
|
|
|
21 |
6 |
p. e304
|
artikel
|
| 8 |
Correction to Lancet Oncol 2019; 20: 1370–85
|
|
|
|
21 |
6 |
p. e304
|
artikel
|
| 9 |
Correction to Lancet Oncol 2019; 20: 1286–94
|
|
|
|
21 |
6 |
p. e304
|
artikel
|
| 10 |
COVID-19 and cancer care in Bermuda
|
Fosker, Christopher
|
|
|
21 |
6 |
p. 761-762
|
artikel
|
| 11 |
COVID-19 and the US health insurance conundrum
|
The Lancet Oncology,
|
|
|
21 |
6 |
p. 733
|
artikel
|
| 12 |
COVID-19: consequences for higher education
|
Burki, Talha Khan
|
|
|
21 |
6 |
p. 758
|
artikel
|
| 13 |
Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America
|
Vasquez, Liliana
|
|
|
21 |
6 |
p. 753-755
|
artikel
|
| 14 |
Effectiveness of anti-PD-1 for hepatocellular carcinoma
|
Liao, Rui
|
|
|
21 |
6 |
p. e293
|
artikel
|
| 15 |
Effectiveness of anti-PD-1 for hepatocellular carcinoma – Authors' reply
|
Qin, Shukui
|
|
|
21 |
6 |
p. e294
|
artikel
|
| 16 |
Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands
|
Dinmohamed, Avinash G
|
|
|
21 |
6 |
p. 750-751
|
artikel
|
| 17 |
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
|
Janjigian, Yelena Y
|
|
|
21 |
6 |
p. 821-831
|
artikel
|
| 18 |
Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?
|
Narita, Yukiya
|
|
|
21 |
6 |
p. 741-743
|
artikel
|
| 19 |
Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care
|
Jones, Daniel
|
|
|
21 |
6 |
p. 748-750
|
artikel
|
| 20 |
Initiation of the Global Coalition for Radiotherapy during the COVID-19 pandemic
|
Price, Pat
|
|
|
21 |
6 |
p. 752-753
|
artikel
|
| 21 |
Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?
|
van Laarhoven, Hanneke WM
|
|
|
21 |
6 |
p. 743-745
|
artikel
|
| 22 |
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
|
Abou-Alfa, Ghassan K
|
|
|
21 |
6 |
p. 796-807
|
artikel
|
| 23 |
Knowing your tumour?
|
Tannock, Ian F
|
|
|
21 |
6 |
p. e297
|
artikel
|
| 24 |
Lenvatinib for thymic carcinomas
|
Takahashi, Nobuyuki
|
|
|
21 |
6 |
p. 745-746
|
artikel
|
| 25 |
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
|
Sato, Jun
|
|
|
21 |
6 |
p. 843-850
|
artikel
|
| 26 |
Less is more? Imaging-based target volume reduction
|
Blais, Eivind
|
|
|
21 |
6 |
p. e302
|
artikel
|
| 27 |
Less is more? Imaging-based target volume reduction – Authors' reply
|
Nestle, Ursula
|
|
|
21 |
6 |
p. e303
|
artikel
|
| 28 |
Minimally invasive surgery and quality of life in cervical cancer
|
Ferrandina, Gabriella
|
|
|
21 |
6 |
p. 746-748
|
artikel
|
| 29 |
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
|
Shu, Catherine A
|
|
|
21 |
6 |
p. 786-795
|
artikel
|
| 30 |
Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer
|
Rosell, Rafael
|
|
|
21 |
6 |
p. 736-738
|
artikel
|
| 31 |
New mitomycin formulation for low-grade upper tract urothelial cancer
|
Dreicer, Robert
|
|
|
21 |
6 |
p. 735-736
|
artikel
|
| 32 |
NIH funding for research underlying new cancer therapies
|
Cleary, Ekaterina Galkina
|
|
|
21 |
6 |
p. 755-757
|
artikel
|
| 33 |
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial
|
Kleinmann, Nir
|
|
|
21 |
6 |
p. 776-785
|
artikel
|
| 34 |
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial
|
Frumovitz, Michael
|
|
|
21 |
6 |
p. 851-860
|
artikel
|
| 35 |
Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
|
Cooney, Tabitha M
|
|
|
21 |
6 |
p. e330-e336
|
artikel
|
| 36 |
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
|
Erker, Craig
|
|
|
21 |
6 |
p. e317-e329
|
artikel
|
| 37 |
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
|
Fangusaro, Jason
|
|
|
21 |
6 |
p. e305-e316
|
artikel
|
| 38 |
Sister Mary Joseph nodule in mantle cell lymphoma
|
O'Connor-Byrne, Niamh
|
|
|
21 |
6 |
p. e337
|
artikel
|
| 39 |
Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic
|
Mauri, Davide
|
|
|
21 |
6 |
p. 759-760
|
artikel
|
| 40 |
Top ten research priorities for pancreatic cancer therapy
|
Klotz, Rosa
|
|
|
21 |
6 |
p. e295-e296
|
artikel
|
| 41 |
Towards greater clarity in the treatment of cholangiocarcinoma
|
de la Fouchardiere, Christelle
|
|
|
21 |
6 |
p. 738-739
|
artikel
|
| 42 |
TRIBE2 results and toxicity
|
Avallone, Antonio
|
|
|
21 |
6 |
p. e299
|
artikel
|
| 43 |
TRIBE2 results and toxicity
|
Zhang, Jianwei
|
|
|
21 |
6 |
p. e298
|
artikel
|
| 44 |
TRIBE2 results and toxicity – Authors' reply
|
Antoniotti, Carlotta
|
|
|
21 |
6 |
p. e300-e301
|
artikel
|
Tijdschrift beschrijving